Table 1 Key characteristics of the study population
|  | Epoetin-ß (n = 68) | Placebo (n = 70) |
|---|---|---|
Age, mean y (±SD) | 59.1 (13.0) | 62.1 (12.3) |
Women, n(%) | 12 (18) | 18 (26) |
Body mass index, mean (±SD) | 28 (4) | 27 (4) |
Diabetes, n(%) | 11 (16) | 10 (14) |
Current smoker, n(%) | 29 (43) | 30 (43) |
Multivessel disease, n(%) | 42 (62) | 50 (71) |
Angiographic LVEF, mean % (±SD) | 46 (8) | 46 (8) |
Infarct related coronary artery, n(%) | ||
 LAD | 34 (50) | 31 (44) |
 RCA | 19 (33.9) | 18 (31.0) |
 LCX | 7 (12.5) | 12 (20.7) |
 LMCA | 0 | 1 (1) |
Initial TIMI flow grade, n(%) | ||
 0 | 35 (52) | 41 (59) |
 1 | 11 (16) | 11 (14) |
 2 | 20 (29) | 15 (21) |
 3 | 2 (3) | 4 (6) |
Final TIMI flow grade, n(%) | ||
 1 | 0 | 1 (1) |
 2 | 5 (7) | 6 (9) |
 3 | 63 (93) | 63 (90) |
Type of intervention, n(%) | ||
 Bare metal stent | 3 (4) | 3 (4) |
 Drug-eluting stent | 63 (93) | 66 (95) |
 Balloon angioplasty | 2 (3) | 1 (1) |
Creatine kinase-MB max, U/L (range) | 201 (121–450) | 213 (124–312) |
Symtom onset to PCI, min (range) | 252 (175–413) | 253 (165–457) |
Hemoglobin max, mean g/dl (±SD) | 14.8 (1.6) | 15 (1.3) |